Prothena Management
Management criteria checks 2/4
Prothena's CEO is Gene Kinney, appointed in Sep 2016, has a tenure of 8.33 years. total yearly compensation is $7.04M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $177.40K. The average tenure of the management team and the board of directors is 7.8 years and 5.5 years respectively.
Key information
Gene Kinney
Chief executive officer
US$7.0m
Total compensation
| CEO salary percentage | 9.0% |
| CEO tenure | 8.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 7.8yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Prothena Surges After Parkinson's Drug Misses Primary Endpoint
Dec 22Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans
Nov 06
Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)
Oct 18Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Oct 02Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares
Jul 26Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Jun 19Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Jun 07New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)
May 14Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Feb 23Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%
Feb 08Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?
Dec 20Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business
Nov 24Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk
Oct 27Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Aug 25What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today
May 10We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth
Apr 23Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook
Mar 01We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate
Dec 28Prothena: Paying A Premium To Cover All The Alzheimer's Bases
Sep 29Prothena GAAP EPS of -$0.88 misses by $0.31
Aug 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$132m |
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$172m |
| Dec 31 2023 | US$7m | US$631k | -US$147m |
| Sep 30 2023 | n/a | n/a | -US$73m |
| Jun 30 2023 | n/a | n/a | -US$141m |
| Mar 31 2023 | n/a | n/a | -US$128m |
| Dec 31 2022 | US$7m | US$601k | -US$117m |
| Sep 30 2022 | n/a | n/a | -US$156m |
| Jun 30 2022 | n/a | n/a | -US$1m |
| Mar 31 2022 | n/a | n/a | US$67m |
| Dec 31 2021 | US$5m | US$573k | US$67m |
| Sep 30 2021 | n/a | n/a | US$69m |
| Jun 30 2021 | n/a | n/a | -US$70m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$3m | US$554k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$102m |
| Jun 30 2020 | n/a | n/a | -US$91m |
| Mar 31 2020 | n/a | n/a | -US$80m |
| Dec 31 2019 | US$3m | US$538k | -US$78m |
| Sep 30 2019 | n/a | n/a | -US$79m |
| Jun 30 2019 | n/a | n/a | -US$84m |
| Mar 31 2019 | n/a | n/a | -US$128m |
| Dec 31 2018 | US$11m | US$525k | -US$156m |
Compensation vs Market: Gene's total compensation ($USD7.04M) is above average for companies of similar size in the US market ($USD3.22M).
Compensation vs Earnings: Gene's compensation has increased whilst the company is unprofitable.
CEO
Gene Kinney (55 yo)
8.3yrs
Tenure
US$7,043,826
Compensation
Dr. Gene G. Kinney, Ph D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.3yrs | US$7.04m | 0.024% $ 177.4k | |
| CFO & Chief Strategy Officer | 11.8yrs | US$2.70m | 0.0060% $ 44.4k | |
| Chief Operating Officer | 3.3yrs | US$2.63m | 0% $ 0 | |
| Chief Regulatory Officer | 8.1yrs | US$2.57m | 0% $ 0 | |
| Chief Accounting Officer & Controller | 11.7yrs | no data | no data | |
| Chief Scientific Officer | 7.6yrs | US$3.34m | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer | no data | US$1.18m | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Chief Development Officer | less than a year | no data | no data | |
| Company Secretary | no data | no data | no data |
7.8yrs
Average Tenure
55yo
Average Age
Experienced Management: PRTA's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.3yrs | US$7.04m | 0.024% $ 177.4k | |
| Independent Director | 2.4yrs | US$896.63k | 0% $ 0 | |
| Independent Director | 12.1yrs | US$912.48k | 0.0023% $ 16.9k | |
| Independent Chairman | less than a year | no data | no data | |
| Independent Chair Emeritus | less than a year | US$923.48k | 0.00045% $ 3.4k | |
| Independent Director | 12.1yrs | US$917.26k | 0% $ 0 | |
| Independent Director | 11.5yrs | US$901.73k | 0.0078% $ 58.4k | |
| Independent Director | 5.5yrs | US$908.48k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$1.70m | no data |
5.5yrs
Average Tenure
64yo
Average Age
Experienced Board: PRTA's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 10:45 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Prothena Corporation plc is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | Barclays |
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |